Salarius Pharmaceuticals, Inc. (SLRX)
NASDAQ: SLRX · Real-Time Price · USD
0.6300
+0.0307 (5.12%)
At close: Aug 1, 2025, 4:00 PM
0.6434
+0.0134 (2.13%)
After-hours: Aug 1, 2025, 7:58 PM EDT

Company Description

Salarius Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing treatments for cancers with unmet medical need.

Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.

The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors.

It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities.

The company is based in Houston, Texas.

Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals logo
CountryUnited States
IndustryBiotechnology
SectorHealthcare
Employees2
CEODavid Arthur

Contact Details

Address:
2450 Holcombe Blvd., Suite X
Houston, Texas 77021
United States
Phone(713) 913-5608
Websitesalariuspharma.com

Stock Details

Ticker SymbolSLRX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001615219
CUSIP Number79400X404
ISIN NumberUS79400X4043
Employer ID46-5087339
SIC Code2834

Key Executives

NamePosition
David J. Arthur M.B.A.Chief Executive Officer, President and Director
Mark J. Rosenblum CPAExecutive Vice President of Finance and Chief Financial Officer

Latest SEC Filings

DateTypeTitle
Jul 31, 20258-KCurrent Report
Jul 31, 2025S-1/A[Amend] General form for registration of securities under the Securities Act of 1933
Jul 29, 20258-KCurrent Report
Jul 28, 20258-KCurrent Report
Jul 21, 20258-KCurrent Report
Jul 14, 20258-KCurrent Report
Jul 8, 20258-KCurrent Report
Jun 16, 2025S-1/A[Amend] General form for registration of securities under the Securities Act of 1933
Jun 16, 20258-KCurrent Report
Jun 11, 20258-KCurrent Report